OpenEvidence, the leading medical search and AI application for U.S. clinicians, has announced a $210 million Series B funding round, valuing the company at $3.5 billion. The round was co-led by Google Ventures and Kleiner Perkins, with follow-on investment from Sequoia Capital (who led their Series A earlier this year). Additional investments came from Coatue, Conviction, and Thrive. OpenEvidence has now raised over $300 million since its inception.
OpenEvidence empowers clinicians to make critical, evidence-based decisions in real-time. It’s actively used in over 10,000 U.S. hospitals and medical centers, with more than 40% of U.S. physicians logging in daily. The platform supports over 8.5 million clinical consultations per month, demonstrating a year-over-year growth of more than 2,000%. This means more than 100 million Americans will be treated by a doctor using OpenEvidence this year.
In an era of overwhelming medical information, where research doubles every five years, OpenEvidence offers a crucial solution. Traditional medical databases are often slow and fragmented, forcing clinicians into time-consuming searches that detract from patient care. Through strategic partnerships with leading medical journals, such as the American Medical Association’s (JAMA) and The New England Journal of Medicine, OpenEvidence enables clinicians to access and synthesize the latest research instantly. Clinicians can input clinical questions or patient details and receive immediate, evidence-based answers with references and follow-up suggestions, accelerating both literature review and clinical decision support. This ultimately leads to improved patient outcomes by rapidly bridging the gap between new research and bedside application.
OpenEvidence DeepConsult: OpenEvidence, founded by Harvard- and MIT-trained PhDs, has also launched OpenEvidence DeepConsult, the first AI agent designed explicitly for physicians. DeepConsult provides every physician with a private, personal team of PhD-level, medically specialized AI agents. These agents can autonomously conduct advanced medical research, analyzing and cross-referencing hundreds of peer-reviewed studies in parallel, even while the physician is away. This capability reveals novel connections across literature that humans might otherwise miss, providing an integrated, interdisciplinary understanding that would typically take months for a human researcher to achieve.
While OpenEvidence’s core search product focuses on rapid answers in 5-10 seconds for quick patient interactions, DeepConsult addresses more in-depth research needs. A physician can pose a complex question before a break and return to a comprehensive, PhD-level research report. This marks a new era of medical productivity, offering tireless, intelligent assistants that can uncover insights and reshape the future of care.
Despite the significant computational cost (over 100 times that of a standard OpenEvidence search), OpenEvidence is offering DeepConsult entirely free to all verified U.S. clinicians, regardless of their institution, reinforcing its mission to support physicians at the point of care.
How the funding will be used: The new funding will be utilized to further expand OpenEvidence’s strategic content partnerships, thereby enhancing its extensive library of advanced medical knowledge. OpenEvidence was founded by serial entrepreneur Daniel Nadler, who previously founded Kensho, an AI company acquired by S&P Global for $700 million in 2018. Nadler was also recently named to the TIME100 Health list of the 100 Most Influential People in global health.
KEY QUOTES:
“At a time when U.S. healthcare faces the dual challenges of clinician burnout and a projected physician shortfall of nearly 100,000 by 2030, the question of AI’s role in bridging the gap is paramount. When physicians’ lives are hard, patients’ lives are harder. OpenEvidence’s commitment to building an AI copilot for clinicians is rooted in the belief that AI will be a force for good in the world, ultimately benefiting both healthcare professionals and the patients they serve. Physicians are superheroes, and OpenEvidence is giving these superheroes new superpowers.”
Daniel Nadler, founder of OpenEvidence
“Daniel Nadler is a magnet for talent, attracting top AI researchers and a world-class medical advisory board. As a firm with a life sciences team largely composed of physicians and scientists, we deeply understand the challenges clinicians face with traditional tools. Physicians are drowning in information but starving for timely insights. OpenEvidence changes that equation, bringing clinicians into the modern era. As early investors in Daniel’s first company, Kensho, GV has been privileged to know him for over a decade. He is a once-in-a-generation founder building one of the fastest-growing technology applications ever seen.”
Sangeen Zeb, General Partner at Google Ventures
“It’s hard to imagine a better use for AI than OpenEvidence. Daniel Nadler and his world-class team are building what I believe will become an AI-era treasure, a life-saving resource for doctors, patients, and their families. I can’t imagine the future without it.”
Investor and Kleiner Perkins Chairman John Doerr—who co-led Google’s original Series A and has served on its board since 1999
“It’s exceptionally rare to see a product reach this level of adoption—let alone among physicians, who are notoriously hard to win over and exacting in what they trust—and the fact that 40% of all physicians in the United States log in daily to OpenEvidence’s software is a staggering signal of both trust and utility. OpenEvidence is not just building a company, they’re setting a new global standard for how evidence-based medical decisions are made. We’re proud to support a mission with this kind of generational ambition.”
Mamoon Hamid, Managing Partner at Kleiner Perkins
“Thus far, the digital transformation of healthcare has mostly fallen short in its efforts to deliver trusted, evidence-based clinical decision support to clinicians when they need it most. The partnership between the American Medical Association, a cornerstone of medical research and analysis for more than a century, and OpenEvidence, my preferred platform for AI-powered clinical insights, represents a significant step toward fulfilling that promise. I’m confident that both clinicians and patients will benefit.”
Robert M. Wachter, MD, Chair of the Department of Medicine at UCSF and author of the upcoming book, A Giant Leap: How AI is Transforming Healthcare and What That Means for Our Future
